 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. PFNX or the Company NYSE American: PFNX in connection with the proposed acquisition of the Company by Ligand Pharmaceuticals Incorporated Ligand NASDAQ: LGND. Under the terms of the acquisition agreement, which is structured like a tender offer, the Companys shareholders will receive 12.00 in cash for each share of PFNX common stock that they own. Additionally, PFNX shareholders will receive a one-time contingent value right of 2.00 CVR in the event a predefined regulatory milestone is achieved by December 31, 2021. 